BioSpace News Archive

Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

The Pharmaceutical Research and Manufacturers of America named Debra DeShong as executive vice president of public affairs.

G3 Translate, a specialized provider of language solutions and communications services, today announced that Amanda Ryan, G3 Life Sciences President, was honored at the WIT Awards on November 12 for her work in the science and technology fields.

Circuit Clinical®, a network of physicians and clinical research professionals devoted to bringing clinical research as a care option to everyone and IZ Medical, a family medicine clinic offering high-quality treatments to patients of all ages, announced a partnership today that will allow IZ Medical’s patient population to participate in clinical research as a care option.

ARUP Laboratories today announced the availability to clients nationwide of a combined test to detect and differentiate COVID-19, influenza, and/or respiratory syncytial virus (RSV) in individuals with respiratory symptoms consistent with COVID-19.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32 nd Annual Virtual Healthcare Conference. Adverum’s video webcast will be accessible on demand beginning today at 10:00 am ET under Events and Presentations in the Investors section of the company’s website. This webcast will

Between 40 and 50 percent of people with Parkinson’s will experience dyskinesia after just five years of taking levodopa. After ten years of taking the medication, this figure jumps to up to 80 percent

PEDSnet study finds 4% of children tested by children’s hospitals since March were positive and most infections were mild, but risk and severity may be higher for children with minority ethnicity or some chronic medical conditions

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms of the lower back, in the Journal of Pain Research. “The published clinical data

ATAI Life Sciences (“ATAI” or the “Company”), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C.